

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

M. Lal

Attorney Docket No.: SNUS121479

Application No.: 10/622,007

Group Art Unit: 1614

Filed:

July 16, 2003

Examiner: --

Title:

PLATINUM COMPOUNDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

March 31, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

- Copies of the listed other information are enclosed for the Examiner's use.
- Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being 2. X filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

Respectfully submitted,

CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC

George E. Renzoni, Ph.D. Registration No. 37,919 Direct Dial No. 206.695.1755

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

GER:md

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS'LLC

1420 Fifth Avenue **Suite 2800** Seattle, Washington 98101

206.682.8100

INFORMATION CITED BY APPLICANT(S) THAT MAY BE MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicant:

M. Lal

Attorney Docket No. SNUS121479

Application No.: 10/622,007

Group Art Unit: 1614

Filed:

July 16, 2003

Examiner: --

Title:

PLATINUM COMPOUNDS

U.S. PATENT DOCUMENTS

*Examiner Cite			Kind	Date	
Initials	No.	Document No.	Code	(mm/dd/yyyy)	Name
	_ U7	4,140,707	Α	02/20/1979	Cleare et al.
	_ U8	4,177,263	Α	12/04/1979	Rosenberg et al.
	U9	6,011,166	Α	01/04/2000	Valsecchi et al.

FOREIGN PATENT DOCUMENTS

*E : O'.			D. 11: -4: D.4-		English	
*Examiner Cite		Kind	Publication Date		Abstract	Translation
Initial No.	Document No.	Code	(mm/dd/yyyy)	Country	Provided	Provided

NONE

*Examiner Cite

OTHER INFORMATION (Including Author, Title, Date, Pertinent Pages, Etc.)

Initial	No.	
	O8	Leonetti, C., et al., "α-Tocherol Protects Against Cisplatin-Induced Toxicity Without Interfering With Antitumor Efficacy," <i>Int. J. Cancer</i> 104(2):243,250, 2003.
	O9	Manzotti, C., et al., "BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin," <i>Clinical Cancer Res.</i> 6:2626-2634, July 2000.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC 1420 Fifth Avenue **Suite 2800** Seattle, Washington 98101 206.682.8100

O10	Martin-Ramos, J.D., et al., "Copper(II) and Nickel(II) Chelated With Dihydrogen Trans-1,2-Diaminocyclohexane-N,N,N'N'-Tetraacetate(2-) Ion (H ₂ CDTA ²⁻). Synthesis, XRD Structure and Properties of [Cu(H ₂ CDTA)] H ₂ O and [Ni(H ₂ CDTA)(H ₂ O)] 4H ₂ O", <i>Polyhedron 15</i> (3)"439-446, 1996.
O11	Pace, A., et al., "Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy," <i>J. Clin. Oncol.</i> 21(5):927-391 March 2003.
Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GER:md

1